Fludarabine and once-daily intravenous busulfan for allogeneic bone marrow transplantation for Chediak-Higashi syndrome.
An HLA-identical sibling bone marrow transplant was done for a patient with Chediak-Higashi syndrome. The preparative regimen included intravenous fludarabine (40 mg/m2/dx4) and busulfan (130 mg/m2/dx4). Busulfan was given once daily. Pharmacokinetic studies showed the area under the concentration-time curve of the once-daily intravenous busulfan was similar to that seen with the total daily dose administered with an every-6-hourly regimen. Toxicity was minimal. Myeloid engraftment occurred on day +17 and donor chimerism was complete. Fludarabine and once-daily intravenous busulfan is well tolerated and is adequate for engraftment of sibling transplant in Chediak-Higashi syndrome.
Gordon
Nancy
N
Division of Pediatrics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030-4009, USA.
Mullen
Craig A
CA
Tran
Hai
H
Worth
Laura
L
Gomez Almaguer
David
D
Chan
Ka Wah
KW
D016026:Bone Marrow Transplantation / Q000276:immunology*; D002066:Busulfan / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002609:Chediak-Higashi Syndrome / Q000601:surgery*; D002675:Child, Preschool; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D035781:Siblings; D013997:Time Factors; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine